Last 12 months
Inside the activity.
4 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 23, 2026 21:06 UTC |
Denton John RusselSee Remarks
|
SaleCommon Stock | 7,500 | $31.82 | $238,626.00 |
DisclosureSEC source: 0002071923-26-000007 · wk-form4_1790197601.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,855 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4. Read SEC document |
| September 17, 2026 Filed Sep 17, 2026 22:08 UTC |
Brille Brian JDirector · See Remarks
|
Exercise / conversionStock Option · Derivative | 400,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0002071959-26-000008 · wk-form4_1789682909.xml · derivative · entry 4 Brille Brian J · CIK 0002071959 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600,000 Underlying: Common Stock · 400,000 shares Expires 2028-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 17, 2026 Filed Sep 17, 2026 22:08 UTC |
Brille Brian JDirector · See Remarks
|
SaleCommon Stock | 400,000 | $30.33 | $12,132,080.00 |
DisclosureSEC source: 0002071959-26-000008 · wk-form4_1789682909.xml · nonDerivative · entry 2 Brille Brian J · CIK 0002071959 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,303 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2026 Filed Sep 17, 2026 22:08 UTC |
Brille Brian JDirector · See Remarks
|
Exercise / conversionCommon Stock | 400,000 | $2.44 | $976,000.00 |
DisclosureSEC source: 0002071959-26-000008 · wk-form4_1789682909.xml · nonDerivative · entry 1 Brille Brian J · CIK 0002071959 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 20:59 UTC |
Spetzler David BaxleyPresident
|
Exercise / conversionStock Option · Derivative | 250,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0002071953-26-000007 · wk-form4_1788555596.xml · derivative · entry 7 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2026-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Exercise of stock options before their expiration date. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 20:59 UTC |
Spetzler David BaxleyPresident
|
SaleCommon Stock | 119,212 | $24.76 | $2,951,116.90 |
DisclosureSEC source: 0002071953-26-000007 · wk-form4_1788555596.xml · nonDerivative · entry 5 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,182,871 F1 · shares: The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 20:59 UTC |
Spetzler David BaxleyPresident
|
Exercise / conversionCommon Stock | 250,000 | $2.44 | $610,000.00 |
DisclosureSEC source: 0002071953-26-000007 · wk-form4_1788555596.xml · nonDerivative · entry 4 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,302,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:59 UTC |
Spetzler David BaxleyPresident
|
Exercise / conversionStock Option · Derivative | 1,000,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0002071953-26-000007 · wk-form4_1788555596.xml · derivative · entry 6 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 1,000,000 shares Expires 2026-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Exercise of stock options before their expiration date. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:59 UTC |
Spetzler David BaxleyPresident
|
SaleCommon Stock | 84,900 | $25.32 | $2,149,676.49 |
DisclosureSEC source: 0002071953-26-000007 · wk-form4_1788555596.xml · nonDerivative · entry 3 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,052,083 F1 · shares: The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:59 UTC |
Spetzler David BaxleyPresident
|
SaleCommon Stock | 393,100 | $24.76 | $9,733,313.24 |
DisclosureSEC source: 0002071953-26-000007 · wk-form4_1788555596.xml · nonDerivative · entry 2 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,136,983 F1 · shares: The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:59 UTC |
Spetzler David BaxleyPresident
|
Exercise / conversionCommon Stock | 1,000,000 | $2.44 | $2,440,000.00 |
DisclosureSEC source: 0002071953-26-000007 · wk-form4_1788555596.xml · nonDerivative · entry 1 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,530,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:44 UTC |
CASTLEMAN PETER MDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001239594-26-000008 · wk-form4_1786743879.xml · nonDerivative · entry 1 CASTLEMAN PETER M · CIK 0001239594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,321 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:43 UTC |
PHILLIPS T DANNYDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001239690-26-000005 · wk-form4_1786743801.xml · nonDerivative · entry 1 PHILLIPS T DANNY · CIK 0001239690 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,060 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:42 UTC |
Minor LloydDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0002038687-26-000007 · wk-form4_1786743756.xml · nonDerivative · entry 1 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,813 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:41 UTC |
Gilliam Joseph EDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001705850-26-000025 · wk-form4_1786743716.xml · nonDerivative · entry 1 Gilliam Joseph E · CIK 0001705850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,321 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:41 UTC |
Fredrickson David PaulDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0002071948-26-000005 · wk-form4_1786743682.xml · nonDerivative · entry 1 Fredrickson David Paul · CIK 0002071948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,813 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:40 UTC |
Vacirca Jeff LDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001724161-26-000008 · wk-form4_1786743631.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,863 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:39 UTC |
JOHANSEN LAURA IDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001189395-26-000002 · wk-form4_1786743580.xml · nonDerivative · entry 1 JOHANSEN LAURA I · CIK 0001189395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,897 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:38 UTC |
HALBERT JONDirector
|
GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001189394-26-000008 · wk-form4_1786743533.xml · nonDerivative · entry 1 HALBERT JON · CIK 0001189394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,813 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:44 UTC |
POSTE GEORGEDirector
|
GrantCommon Stock | 1,600 | $15.62 | $24,992.00 |
DisclosureSEC source: 0001180770-26-000003 · wk-form4_1780436653.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,729 F1 · kind: Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026. F2 · balance_after: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:43 UTC |
Knowles Jonathan Kenneth CharlesDirector
|
GrantCommon Stock | 1,600 | $15.62 | $24,992.00 |
DisclosureSEC source: 0001662103-26-000002 · wk-form4_1780436576.xml · nonDerivative · entry 1 Knowles Jonathan Kenneth Charles · CIK 0001662103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,979 F1 · kind: Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026. Read SEC document |
| May 15, 2026 Filed May 18, 2026 16:22 UTC |
HALBERT DAVID DDirector · See Remarks · 10% owner
|
Tax withholdingCommon Stock | 40,712 | $15.25 | $620,858.00 |
DisclosureSEC source: 0001034380-26-000004 · wk-form4_1779135727.xml · nonDerivative · entry 1 HALBERT DAVID D · CIK 0001034380 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,574,533 F1 · shares: Shares withheld for the payment of taxes on the vesting and settlement of RSUs. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:23 UTC |
Denton John RusselSee Remarks
|
Tax withholdingCommon Stock | 6,047 | $15.25 | $92,216.75 |
DisclosureSEC source: 0002071923-26-000005 · wk-form4_1779135826.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,515 F1 · shares: Shares withheld for the payment of taxes on the vesting and settlement of RSUs. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:23 UTC |
Power Luke ThomasSee Remarks
|
Tax withholdingCommon Stock | 9,771 | $15.25 | $149,007.75 |
DisclosureSEC source: 0002072013-26-000004 · wk-form4_1779135806.xml · nonDerivative · entry 1 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,771 F1 · shares: Shares withheld for the payment of taxes on the vesting and settlement of RSUs. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:23 UTC |
Spetzler David BaxleyPresident
|
Tax withholdingCommon Stock | 13,856 | $15.25 | $211,304.00 |
DisclosureSEC source: 0002071953-26-000004 · wk-form4_1779135792.xml · nonDerivative · entry 1 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,083 F1 · shares: Shares withheld for the payment of taxes on the vesting and settlement of RSUs. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:23 UTC |
Brille Brian JDirector · See Remarks
|
Tax withholdingCommon Stock | 13,987 | $15.25 | $213,301.75 |
DisclosureSEC source: 0002071959-26-000006 · wk-form4_1779135780.xml · nonDerivative · entry 1 Brille Brian J · CIK 0002071959 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,303 F1 · shares: Shares withheld for the payment of taxes on the vesting and settlement of RSUs. Read SEC document |
| May 15, 2026 Filed Jul 13, 2026 11:06 UTC |
HALBERT JONDirector
|
PurchaseCommon Stock | 68,000 | $14.56 | $990,080.00 |
DisclosureSEC source: 0001189394-26-000005 · wk-form4_1783940766.xml · nonDerivative · entry 3 HALBERT JON · CIK 0001189394 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LAH Investments, Ltd. Disclosed balance after: 704,598 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · balance_after: Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| May 11, 2026 Filed May 12, 2026 12:22 UTC |
Vacirca Jeff LDirector
|
PurchaseCommon Stock | 31,050 | $16.15 | $501,426.45 |
DisclosureSEC source: 0001724161-26-000005 · wk-form4_1778588549.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,671 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.13 to $16.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 17:55 UTC |
HALBERT DAVID DDirector · See Remarks · 10% owner
|
GrantCommon Stock | 320,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001034380-26-000002 · wk-form4_1773179739.xml · nonDerivative · entry 1 HALBERT DAVID D · CIK 0001034380 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,615,245 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:01 UTC |
Power Luke ThomasSee Remarks
|
GrantCommon Stock | 63,971 | $0.00 | $0.00 |
DisclosureSEC source: 0002072013-26-000002 · wk-form4_1773180079.xml · nonDerivative · entry 1 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,542 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC |
Denton John RusselSee Remarks
|
GrantCommon Stock | 63,971 | $0.00 | $0.00 |
DisclosureSEC source: 0002071923-26-000002 · wk-form4_1773180021.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,562 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:59 UTC |
Spetzler David BaxleyPresident
|
GrantCommon Stock | 83,162 | $0.00 | $0.00 |
DisclosureSEC source: 0002071953-26-000002 · wk-form4_1773179995.xml · nonDerivative · entry 1 Spetzler David Baxley · CIK 0002071953 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,939 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:59 UTC |
Brille Brian JDirector · See Remarks
|
GrantCommon Stock | 83,162 | $0.00 | $0.00 |
DisclosureSEC source: 0002071959-26-000004 · wk-form4_1773179971.xml · nonDerivative · entry 1 Brille Brian J · CIK 0002071959 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,290 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 23:09 UTC |
Vacirca Jeff LDirector
|
GrantCommon Stock | 2,492 | $20.06 | $49,989.52 |
DisclosureSEC source: 0001724161-26-000002 · wk-form4_1772233759.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,621 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 23:08 UTC |
Fredrickson David PaulDirector
|
GrantCommon Stock | 2,492 | $20.06 | $49,989.52 |
DisclosureSEC source: 0002071948-26-000002 · wk-form4_1772233729.xml · nonDerivative · entry 1 Fredrickson David Paul · CIK 0002071948 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,621 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 23:08 UTC |
PHILLIPS T DANNYDirector
|
GrantCommon Stock | 3,739 | $20.06 | $75,004.34 |
DisclosureSEC source: 0001239690-26-000002 · wk-form4_1772233679.xml · nonDerivative · entry 1 PHILLIPS T DANNY · CIK 0001239690 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,868 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 23:08 UTC |
HALBERT JONDirector
|
GrantCommon Stock | 2,492 | $20.06 | $49,989.52 |
DisclosureSEC source: 0001189394-26-000002 · wk-form4_1772233706.xml · nonDerivative · entry 1 HALBERT JON · CIK 0001189394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,621 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 23:07 UTC |
CASTLEMAN PETER MDirector
|
GrantCommon Stock | 5,509 | $20.06 | $110,510.54 |
DisclosureSEC source: 0001239594-26-000005 · wk-form4_1772233651.xml · nonDerivative · entry 1 CASTLEMAN PETER M · CIK 0001239594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,138 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 12:48 UTC |
Minor LloydDirector
|
GrantCommon Stock | 2,492 | $20.06 | $49,989.52 |
DisclosureSEC source: 0002038687-26-000004 · wk-form4_1772455734.xml · nonDerivative · entry 1 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,621 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 23:37 UTC |
CASTLEMAN PETER MDirector
|
Exercise / conversionStock Option · Derivative | 2,500 | $0.00 Strike: $18.60 | $0.00 |
DisclosureSEC source: 0001239594-26-000003 · wk-form4_1768347427.xml · derivative · entry 4 CASTLEMAN PETER M · CIK 0001239594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2035-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 23:37 UTC |
CASTLEMAN PETER MDirector
|
Exercise / conversionCommon Stock | 2,500 | $18.60 | $46,500.00 |
DisclosureSEC source: 0001239594-26-000003 · wk-form4_1768347427.xml · nonDerivative · entry 1 CASTLEMAN PETER M · CIK 0001239594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:39 UTC |
Power Luke ThomasSee Remarks
|
Exercise / conversionStock Option · Derivative | 37,500 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0002072013-25-000006 · wk-form4_1765586352.xml · derivative · entry 6 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2028-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:39 UTC |
Power Luke ThomasSee Remarks
|
Exercise / conversionStock Option · Derivative | 24,750 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0002072013-25-000006 · wk-form4_1765586352.xml · derivative · entry 5 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,750 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:39 UTC |
Power Luke ThomasSee Remarks
|
SaleCommon Stock | 1,400 | $27.16 | $38,017.56 |
DisclosureSEC source: 0002072013-25-000006 · wk-form4_1765586352.xml · nonDerivative · entry 4 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,571 F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:39 UTC |
Power Luke ThomasSee Remarks
|
SaleCommon Stock | 60,850 | $26.56 | $1,616,443.74 |
DisclosureSEC source: 0002072013-25-000006 · wk-form4_1765586352.xml · nonDerivative · entry 3 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,971 F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:39 UTC |
Power Luke ThomasSee Remarks
|
Exercise / conversionCommon Stock | 37,500 | $2.44 | $91,500.00 |
DisclosureSEC source: 0002072013-25-000006 · wk-form4_1765586352.xml · nonDerivative · entry 2 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:39 UTC |
Power Luke ThomasSee Remarks
|
Exercise / conversionCommon Stock | 24,750 | $2.44 | $60,390.00 |
DisclosureSEC source: 0002072013-25-000006 · wk-form4_1765586352.xml · nonDerivative · entry 1 Power Luke Thomas · CIK 0002072013 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 23:22 UTC |
Brille Brian JDirector · See Remarks
|
GiftCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0002071959-25-000009 · wk-form4_1765581770.xml · nonDerivative · entry 2 Brille Brian J · CIK 0002071959 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,128 Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 23:22 UTC |
Brille Brian JDirector · See Remarks
|
GiftCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0002071959-25-000009 · wk-form4_1765581770.xml · nonDerivative · entry 1 Brille Brian J · CIK 0002071959 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,778 Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 13:12 UTC |
Denton John RusselSee Remarks
|
PurchaseCommon Stock | 4,184 | $24.09 | $100,792.56 |
DisclosureSEC source: 0002071923-25-000009 · wk-form4_1762780360.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 9,184 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.99 to $24.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.